EA201491455A1 - ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA201491455A1
EA201491455A1 EA201491455A EA201491455A EA201491455A1 EA 201491455 A1 EA201491455 A1 EA 201491455A1 EA 201491455 A EA201491455 A EA 201491455A EA 201491455 A EA201491455 A EA 201491455A EA 201491455 A1 EA201491455 A1 EA 201491455A1
Authority
EA
Eurasian Patent Office
Prior art keywords
effectors
arrestina
compositions
methods
arrestin
Prior art date
Application number
EA201491455A
Other languages
English (en)
Russian (ru)
Inventor
Дэннис Ямашита
Сяо Тао Чэнь
Original Assignee
Тревена, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тревена, Инк. filed Critical Тревена, Инк.
Publication of EA201491455A1 publication Critical patent/EA201491455A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201491455A 2012-01-31 2013-01-30 ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA201491455A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592887P 2012-01-31 2012-01-31
PCT/US2013/023808 WO2013116312A1 (en) 2012-01-31 2013-01-30 ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
EA201491455A1 true EA201491455A1 (ru) 2015-01-30

Family

ID=48870731

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491455A EA201491455A1 (ru) 2012-01-31 2013-01-30 ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (14)

Country Link
US (2) US8946142B2 (enExample)
EP (1) EP2809337A4 (enExample)
JP (1) JP6225121B2 (enExample)
KR (1) KR20140132340A (enExample)
CN (1) CN104168907A (enExample)
AU (1) AU2013215269A1 (enExample)
BR (1) BR112014018709A8 (enExample)
CA (1) CA2862933A1 (enExample)
EA (1) EA201491455A1 (enExample)
HK (1) HK1203379A1 (enExample)
IL (1) IL233826A0 (enExample)
MX (1) MX2014009233A (enExample)
NZ (1) NZ627995A (enExample)
WO (1) WO2013116312A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201491455A1 (ru) * 2012-01-31 2015-01-30 Тревена, Инк. ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3208861A1 (en) 2016-02-19 2017-08-23 Novaled GmbH Electron transport layer comprising a matrix compound mixture for an organic light-emitting diode (oled)
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925345A (en) * 1974-05-10 1975-12-09 Francis Merlin Bumpus (sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4547489A (en) 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
EP0358418B1 (en) * 1988-09-05 1992-12-16 Sankyo Company Limited Cyclic peptide, its preparation and its use in the treatment of cardiovascular disorders
GB8822483D0 (en) 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
CA2090401A1 (en) 1990-08-27 1992-02-28 Deborah A. Rathjen Method of treating viral infection
AU1256692A (en) 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
PT730465E (pt) 1993-09-24 2002-06-28 Univ Southern California Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6165978A (en) 1997-12-12 2000-12-26 University Of Southern California Wound healing composition
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20050202029A1 (en) 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
US8038992B2 (en) 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
CN102333536B (zh) * 2008-12-29 2014-08-13 特维那公司 β-抑制蛋白效应器和组合物以及其应用方法
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
JP5925771B2 (ja) * 2010-06-24 2016-05-25 トラスティーズ オブ タフツ カレッジ ナイアシン模倣体、およびその使用方法
EA201491455A1 (ru) * 2012-01-31 2015-01-30 Тревена, Инк. ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Also Published As

Publication number Publication date
JP2015506960A (ja) 2015-03-05
CN104168907A (zh) 2014-11-26
US20130196902A1 (en) 2013-08-01
WO2013116312A1 (en) 2013-08-08
AU2013215269A1 (en) 2014-08-21
EP2809337A1 (en) 2014-12-10
US8946142B2 (en) 2015-02-03
CA2862933A1 (en) 2013-08-08
BR112014018709A2 (enExample) 2017-06-20
BR112014018709A8 (pt) 2017-07-11
JP6225121B2 (ja) 2017-11-01
HK1203379A1 (en) 2015-10-30
MX2014009233A (es) 2015-05-15
NZ627995A (en) 2016-12-23
US20150105316A1 (en) 2015-04-16
IL233826A0 (en) 2014-09-30
KR20140132340A (ko) 2014-11-17
EP2809337A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
EA201590987A1 (ru) Соединения и способы их применения
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA202193044A2 (ru) Способы лечения таупатии
EA201590997A1 (ru) Соединения и способы их применения
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201400178A1 (ru) Лечение рака молочной железы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201400579A1 (ru) Антитела к il-36r
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
EA201490559A1 (ru) Композиция для лечения свища
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201490688A1 (ru) 2-тиопиримидиноны
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201400748A1 (ru) Композиция для обработки семян
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний